Monitor for IND filing updates on APVO451 in 1H2027 and any future scientific conference presentations for additional pipeline details. No near-term catalyst is tied to this announcement.
Price Chart
Executive Summary
Aptevo Therapeutics announced progress in its next-generation trispecific programs, focusing on scalable manufacturing for lead candidate APVO451, with IND-enabling studies expected in 1H2027. This is an early-stage pipeline update with no financial data or clinical results, representing a routine developmental milestone for a clinical-stage biotech.
Key Facts
- Aptevo is optimizing several trispecific candidates for scalable manufacturing, a step toward human testing.
- Lead candidate APVO451 is expected to enter IND-enabling studies in 1H2027.
- No financial data, clinical results, or partnership announcements were disclosed.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company.
Risk Factors
- Pre-clinical stage; no guarantee of successful IND filing or clinical trial initiation.
- Scalable manufacturing challenges could delay timelines.
- No disclosed financial runway or partnership to support development costs.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-400213 |
| Document: apvo-ex99_1.htm | 0001193125-26-400213 |
| Document: 0001193125-26-400213-index-headers.html | 0001193125-26-400213 |
| Document: 0001193125-26-400213-index.html | 0001193125-26-400213 |
| Document: 0001193125-26-400213.txt | 0001193125-26-400213 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.73 | awaiting T+5 | — | $1.73 (−0.10%) |
Oct 23, 2026 2d ago | 8-K | $1.61 | awaiting T+5 | — | $1.73 (+7.45%) |
Oct 14, 2026 12d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.73 (+0.00%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.73 (−5.46%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.73 (+1.17%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.73 (−1.17%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.73 (−41.16%) |
Jul 27, 2026 12w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.73 (−58.91%) |
Jun 30, 2026 16w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.73 (−61.12%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.73 (−64.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers